more

Aeglea BioTherapeutics, Inc. (AGLE)

(Delayed Data from NSDQ)

$6.96 USD

+0.24 (3.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.94 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

by Zacks Equity Research Published on May 25,2022

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

biotechs

AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate

by Zacks Equity Research Published on May 23,2022

AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.

pharmaceuticals

Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata

by Zacks Equity Research Published on May 23,2022

The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.

pharmaceuticals

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research Published on May 20,2022

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.

Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

by Zacks Equity Research Published on May 19,2022

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

biotechs

Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

by Zacks Equity Research Published on May 18,2022

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

biotechs

Horizon (HZNP) Begins Enrollment in Alopecia Areata Study

by Zacks Equity Research Published on May 18,2022

Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.

biotechs

Seagen's (SGEN) Stock Up on CEO's Resignation Announcement

by Zacks Equity Research Published on May 17,2022

Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.

biotechs

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

by Zacks Equity Research Published on May 13,2022

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

biotechs

Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs

by Zacks Equity Research Published on May 11,2022

Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.

Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on May 05,2022

Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA

by Zacks Equity Research Published on April 13,2022

Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA. Shares down.

biotechs

Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on March 08,2022

Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 04,2021

Aeglea (AGLE) delivered earnings and revenue surprises of -6.90% and 1.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AGLEPositive Net Change

Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 05,2021

Aeglea (AGLE) delivered earnings and revenue surprises of 47.37% and 112.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?